TY - JOUR
T1 - Prognostic significance of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase-1 (IDH-1) mutation in glioblastoma multiforme patients
T2 - A single-center experience in the Middle East region
AU - Ayoub, Zeina
AU - Geara, Fady
AU - Najjar, Marwan
AU - Comair, Youssef
AU - Khoueiry-Zgheib, Nathalie
AU - Khoueiry, Pierre
AU - Mahfouz, Rami
AU - Boulos, Fouad I.
AU - Kamar, Francois G.
AU - Andraos, Therese
AU - Saadeh, Fadi
AU - Kreidieh, Firas
AU - Abboud, Miguel
AU - Skaf, Ghassan
AU - Assi, Hazem I.
N1 - Funding Information:
A seed grant from the American University of Beirut provided financial funding of our study.
Publisher Copyright:
© 2019 Elsevier B.V.
PY - 2019/7
Y1 - 2019/7
N2 - Objectives: To determine the prevalence and prognostic value of MGMT promoter methylation and IDH1 mutation in glioblastoma multiforme (GBM) patients from the Middle East. Patients and methods: Records of patients diagnosed between 2003 and 2015 were reviewed. MGMT promoter methylation was measured using methylation-specific polymerase chain reaction and IDH-1 mutation was reported. The primary endpoint was overall survival (OS). Results: A total of 110 patients were included. The median age was 51 years and 71 patients (64.5%) were males. The median diameter of GBM was 4.6 cm and 29 patients (26.4%) had multifocal disease. Gross total resection was achieved in 38 patients (24.9%). All patients received adjuvant radiation therapy, and 96 patients (91.4%) received concomitant temozolomide. At a median follow up of 13.6 months, the median OS was 17.2 months, and the OS at 1 and 2 years were 71.6% and 34.8%, respectively. On multivariate analysis, age at diagnosis (HR 1.019; P = 0.044) and multifocality (HR 2.373; P = 0.001) were the only independent prognostic variables. MGMT promoter methylation was found in 28.2% of patients but did not significantly correlate with survival (HR 1.160; P = 0.635). IDH-1 mutation was found in 10% of patients was associated with a non-significant trend for survival improvement (HR 0.502; P = 0.151). Conclusion: Patients with GBM from the Middle East have adequate survival outcomes when given the optimal treatment. In our patient population, MGMT promoter methylation did not seem to correlate with outcomes, but patients with IDH1 mutation had numerically higher survival outcomes.
AB - Objectives: To determine the prevalence and prognostic value of MGMT promoter methylation and IDH1 mutation in glioblastoma multiforme (GBM) patients from the Middle East. Patients and methods: Records of patients diagnosed between 2003 and 2015 were reviewed. MGMT promoter methylation was measured using methylation-specific polymerase chain reaction and IDH-1 mutation was reported. The primary endpoint was overall survival (OS). Results: A total of 110 patients were included. The median age was 51 years and 71 patients (64.5%) were males. The median diameter of GBM was 4.6 cm and 29 patients (26.4%) had multifocal disease. Gross total resection was achieved in 38 patients (24.9%). All patients received adjuvant radiation therapy, and 96 patients (91.4%) received concomitant temozolomide. At a median follow up of 13.6 months, the median OS was 17.2 months, and the OS at 1 and 2 years were 71.6% and 34.8%, respectively. On multivariate analysis, age at diagnosis (HR 1.019; P = 0.044) and multifocality (HR 2.373; P = 0.001) were the only independent prognostic variables. MGMT promoter methylation was found in 28.2% of patients but did not significantly correlate with survival (HR 1.160; P = 0.635). IDH-1 mutation was found in 10% of patients was associated with a non-significant trend for survival improvement (HR 0.502; P = 0.151). Conclusion: Patients with GBM from the Middle East have adequate survival outcomes when given the optimal treatment. In our patient population, MGMT promoter methylation did not seem to correlate with outcomes, but patients with IDH1 mutation had numerically higher survival outcomes.
KW - Glioblastoma multiforme
KW - IDH-1 mutation
KW - MGMT promoter methylation
KW - Middle East region
UR - http://www.scopus.com/inward/record.url?scp=85065721797&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065721797&partnerID=8YFLogxK
U2 - 10.1016/j.clineuro.2019.04.008
DO - 10.1016/j.clineuro.2019.04.008
M3 - Article
C2 - 31108342
AN - SCOPUS:85065721797
SN - 0303-8467
VL - 182
SP - 92
EP - 97
JO - Clinical Neurology and Neurosurgery
JF - Clinical Neurology and Neurosurgery
ER -